Telemetrically monitored arrhythmogenic effects of doxorubicin in a dog model of heart failure

Pathophysiology

Volumn 9, Issue 4, 2003, Pages 241-248

  Vaynblat, Mikhail ^a   Pagala, Murali K ^a   Davis III, Wellington J ^a   Bhaskaran, Dinesh ^a   Fazylov, Rafael ^a   Gelbstein, Chaya ^a   Greengart, Alvin ^a   Cunningham Jr , Joseph N ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Antineoplastic drugs; Arrhythmias; Cardiotoxicity; Telemetry

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTINEOPLASTIC AGENT; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; ASYSTOLE; CARDIOTOXICITY; CONTROLLED STUDY; DEVICE; DISEASE COURSE; DOG; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART DILATATION; HEART FAILURE; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; INTRACORONARY INFUSION; MALE; MONITORING; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; QRS COMPLEX; SUDDEN DEATH; TELEMETRY;

EID: 0142027256     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4680(03)00026-9     Document Type: Article

References (39)

1. Iyengar S.R.K., Charnette E.J.P., Iyendor C.K.S., Lynn R.V. An experimental model with left ventricular hypertrophy caused by subcoronary aortic stenosis in dogs. J. Thorac. Cardiovasc. Surg. 66:1973;823-827.
2. Smith H.J., Nuttall A. Experimental model of heart failure. Cardiovasc. Res. 19:1985;181-186.
3. Wilson J.R., Douglas P., Hickey W.F., et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation. 75:1987;857-867.
4. Lavine S.J., Prcevski P., Held C., Johnson V. Experimental model of chronic global left ventricular dysfunction secondary to left coronary microembolization. J. Am. Coll. Cardiol. 18:1991;1794-1803.
5. McDonald K.M., Francis G.S., Carlyle P.F., Hauer K., Mathews J., Hunter T.W., Cohn J.N. Hemodynamic left ventricular structural and hormonal changes after discrete myocardial damage in the dog. J. Am. Coll. Cardiol. 19:1992;460-467.
6. Mettler F.P., Young D.M., Ward J.M. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 37:1977;2705-2713.
7. Gralla E.J., Fleischman R.W., Luthra Y.K., Stadnicki S.W. The dosing schedule dependent toxicities of Adriamycin in beagle dogs and rhesus monkeys. Toxicology. 13:1979;263-273.
8. Von Fleet J.F., Ferrous V.J., Weirich W.E. Cardiac disease induced by chronic Adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am. J. Pathol. 99:1980;13-42.
9. Ditchey R.V., LeWinter M.M., Higgins C.B. Acute effect of doxorubicin (Adriamycin) on left ventricular function in dogs. Int. J. Cardiol. 6:1984;341-350.
10. De Marco A., Gaetani M., Scarpinato B. Adriamycin (NSC-123127): a new antibiotic with antitumor activity. Cancer Chemother. Rep. 53:1969;33-37.
11. Gottlieb J.A., . Hill C.S., Ibanez M.L., Clark R.L. Chemotherapy of thyroid cancer. Cancer. 30:1972;848-853.
12. Weiss R.B., Sarosy G., Clagett-Carr K., Russo M., Leyland-Jones B. Anthracycline analogs: the past, present, and future. Cancer Chemother. Pharmacol. 18:1986;185-197.
13. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 32:1973;302-314.
14. Steinhertz I.J., Steinhertz P.G., Tan C.T.C., Heller G., Murphy I. Cardiotoxicity 4 to 20 years after completing anthracycline therapy. J. Am. Med. Assoc. 266:1991;1672-1677.
15. Felker G.M., Hu W., Hare J.M., Hruban R.H., Baughman K.L., Kasper E.K. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1278 patients. Medicine. 78:1999;270-283.
16. Magovern J.A., Christlieb I.Y., Badylak S.F., Lantz G.C., Kao R.L. A model of left ventricular dysfunction caused by intracoronary doxorubicin. Ann. Thorac. Surg. 53:1992;861-863.
17. Shah H.R., Vaynblat M., Ramdev G., Cunningham J.N., Chiavarelli M. Experimental cardiomyopathy as a model of chronic heart failure. J. Invest. Surg. 10:1997;387-396.
18. Monnet E., Orton E.C. A canine model of heart failure by intracoronary adriamycin injection: hemodynamic and energetic results. J. Card. Fail. 5:1999;255-264.
19. Vaynblat M., Chiavarelli M., Shah H.R., Ramdev G., Aron M., Zisbrod Z., Cunningham J.N. Cardiac binding in experimental heart failure. Ann. Thorac. Surg. 64:1997;81-85.
20. Meinertz T., Hofmann T., Kasper W., et al. Significance of ventricular arrhythmias in ideopathic dilated cardiomyopathy. Am. J. Cardiol. 53:1984;902-907.
21. Anderson K.P., Freedman R.A., Mason J.W. Sudden death in idiopathic dilated cardiomyopathy. Ann. Intern. Med. 107:1987;104-106.
22. Hofmann T., Meinertz T., Kasper W., et al. Mode of death in ideopathic dilated cardiomyopathy: a multivariate analysis of prognostic determinants. Am. J. Heart. 116:1988;1455-1463.
23. Brockway B.P., Hassler C.R. Application of radiotelemetry to cardiovascular measurements in pharmacology and toxicology. Salem H., Baskin S.I. New Technologies and Concepts for Reducing Drug Toxicity. 1993;109-132 CRC Press, Boca Raton, FL.
24. Kramer K., Kinter L., Brockway B.P., Voss H., Remie R., Van Zutphen B.L.M. The use of radiotelemetry in small laboratory animals: recent advances. Am. Assoc. Lab. Anim. Sci. 4:2001;8-26. Contemporary topics.
25. Doroshow J.H., Locker G.Y. Role of oxygen radical formation in anthracycline cardiac toxicity. Muggia F.M., Young C.W., Carter S.K. Anthracycline Antibiotics in Cancer Therapy. 1982;Martinus Nijhoff, Le Hague.
26. Doroshow J.H., Tallent C., Schechter J.E. Ultrastructural features of adriamycin-induced skeletal and cardiac muscle toxicity. Am. J. Pathol. 118:1985;288-297.
27. Monti E., Piccinini F., Villani F., Favalli L. Myocardial contractility and heart pharmacokinetic of adriamycin following a single administration in rat. Cancer Chemother. Pharmacol. 18:1986;289-291.
28. Villani F., Monti E., Piccinini F., Favalli L., Lanza E., Rozza A., Poggi P. Relationship between ECG changes and myocardial morphological alterations induced by adriamycin in rat. Tumori. 72:1986;339-344.
29. Timour Q., Nony P., Lang J., Lakhal M., Veronique T., Faucon G. Doxorubicin concentration in plasma and myocardium and their responsive roles in cardiotoxicity. Card. Drug Ther. 1:1988;559-560.
30. Singal P.K., Deally C.M.R., Weinberg L.E. Subcellular effects of adriamycin in the heart: a concise review. J. Cell. Mol. Cardiol. 19:1987;817-828.
31. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin. Semin. Oncol. 19:1992;670-685.
32. Herman E.H., Matre R.M., Lee I.P., Vick J., Warardekary V.A. A comparison of the cardiovascular actions of daunomycin, adriamycin and M-acetyl-daunomycin in hamsters and monkeys. Pharmacology. 6:1971;230-241.
33. Cirillo R., Sacco G., Venturella S., Brightwell J., Giachetti A., Manzini S. Comparison of doxorubicin- and MEN 10755-induced long term progressive cardiotoxicity in the rat. J. Cardiovasc. Pharmacol. 35:2000;100-108.
34. Singal P.K., Iliskovic N., Li T., Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 11:1997;931-936.
35. Buja I.M., Ferrans V.J., Mayer M.J., Roberts W.C., Henderson E.S. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer. 32:1973;771-778.
36. Bigger J.T. Jr. Cardiac Arrhythmias. Wyngaarden J.B., Smith L.H. Jr, Bennett J.C. Cecil Textbook of Medicine. 1992;W.B. Saunders Company.
37. 2+ binding and lipid peroxidation but depresses myocardial function. Am. J. Physiol. 250:1986;H419-H425.
38. Singal P.K., Panagia V. Direct effects of adriamycin on the rat heart sarcolemma. Res. Commun. Chem. Pathol. Pharmacol. 43:1984;67-77.
39. Olson H.M., Young D.M., Prieur D.J., et al. Electrolyte and morphologic alterations of myocardium in adreamycin-treated rabbits. Am. J. Pathol. 77:1974;439-454.